PAS-004 in Patients With Advanced Solid Tumors

计划入组 48 人 · 首次发布于 2024 年 3 月 8 日

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

计划入组 91 人 · 首次发布于 2021 年 5 月 19 日

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

计划入组 29 人 · 首次发布于 2024 年 3 月 1 日

MAPK pathway inhibitor (cancer)

prenylated flavonoids(University of Mississippi/Xiamen University/Jinan University)

MAPK signaling pathway inhibitors (Columbia University/Columbia Technology Ventures)

Pathway Therapeutics, Inc.

United States

Erasca

United States

Kura Oncology

United States

Immuneering Partners with Lilly for Phase 2 NSCLC Combination Trial Testing Dual MAPK Pathway Blockade

Pasithea Therapeutics Secures $60 Million Funding to Advance MEK Inhibitor for Neurofibromatosis Treatment

PAS-004 Shows Favorable Safety and Early Efficacy in MAPK-Driven Solid Tumors